Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS Comput Biol. 2012 Jan;8(1):e1002339. doi: 10.1371/journal.pcbi.1002339. Epub 2012 Jan 5.

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.

Author information

  • 1Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, USA. bambang_adiwijaya@vrtx.com

Abstract

We propose an integrative, mechanistic model that integrates in vitro virology data, pharmacokinetics, and viral response to a combination regimen of a direct-acting antiviral (telaprevir, an HCV NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chronic hepatitis C (CHC). This model, which was parameterized with on-treatment data from early phase clinical studies in treatment-naïve patients, prospectively predicted sustained virologic response (SVR) rates that were comparable to observed rates in subsequent clinical trials of regimens with different treatment durations in treatment-naïve and treatment-experienced populations. The model explains the clinically-observed responses, taking into account the IC50, fitness, and prevalence prior to treatment of viral resistant variants and patient diversity in treatment responses, which result in different eradication times of each variant. The proposed model provides a framework to optimize treatment strategies and to integrate multifaceted mechanistic information and give insight into novel CHC treatments that include direct-acting antiviral agents.

© 2012 Adiwijaya et al.

PMID:
22241977
[PubMed - indexed for MEDLINE]
PMCID:
PMC3252270
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk